Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation

Yuan-Jie Liu,1– 3,&ast; Sheng-Yan Yin,2,3,&ast; Shu-Hong Zeng,2,3 Yi-Dou Hu,1 Meng-Qi Wang,2,3 Pan Huang,1 Jie-Pin Li1– 3 1Department of Oncology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, 215600, People’s Republic of China; 2Affil...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu YJ, Yin SY, Zeng SH, Hu YD, Wang MQ, Huang P, Li JP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	gastric cancer lhfpl6 biomarker emt m2 macrophages Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/1ee5f4adf0d14b43b2df0bf2afc698ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1ee5f4adf0d14b43b2df0bf2afc698ed
record_format	dspace
spelling	oai:doaj.org-article:1ee5f4adf0d14b43b2df0bf2afc698ed2021-11-21T19:08:51ZPrognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation1178-7066https://doaj.org/article/1ee5f4adf0d14b43b2df0bf2afc698ed2021-11-01T00:00:00Zhttps://www.dovepress.com/prognostic-value-of-lhfpl-tetraspan-subfamily-member-6-lhfpl6-in-gastr-peer-reviewed-fulltext-article-PGPMhttps://doaj.org/toc/1178-7066Yuan-Jie Liu,1– 3,&ast; Sheng-Yan Yin,2,3,&ast; Shu-Hong Zeng,2,3 Yi-Dou Hu,1 Meng-Qi Wang,2,3 Pan Huang,1 Jie-Pin Li1– 3 1Department of Oncology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, 215600, People’s Republic of China; 2Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, 210029, People’s Republic of China; 3No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jie-Pin Li; Pan HuangDepartment of Oncology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Chang ‘an South Road No. 77, Zhangjiagang, Jiangsu, 215600, People’s Republic of ChinaTel +8615150224526; +8613921976647Email zjgzy027@njucm.edu.cn; yezipan2020@126.comPurpose: The identification of biomarkers and effective therapeutic targets for gastric cancer (GC), the most common cause of cancer-related deaths around the world, is currently a major focus in research. Here, we examined the utility of LHFPL6 as a prognostic biomarker and therapeutic target for GC.Methods: We explored the clinical relevance, function, and molecular role of LHFPL6 in GC using the MethSurv, cBioPortal, TIMER, Gene Expression Profiling Interactive Analysis, ONCOMINE, MEXPRESS, and EWAS Atlas databases. The GSE118919, GSE29272, and GSE13861 datasets were used for differential expression analysis. Using The Cancer Genome Atlas, we developed a Cox regression model and assessed the clinical significance of LHFPLs. In addition, we used the “CIBERSORT” algorithm to make reliable immune infiltration estimations. Western blot and immunohistochemistry were used to examine protein expression. Cell migration and invasion were assessed using transwell experiments. THP-1-derived macrophages and GC cells were co-cultured in order to model tumor–macrophage interactions in vitro. The levels of CD206 and CD163 were measured using immunofluorescence assays. The results were visualized with the “ggplot2” and “circlize” packages.Results: Our results showed that in GC, LHFPL6 overexpression was significantly associated with a poor prognosis. Our findings also suggested that LHFPL6 may be involved in the activation of the epithelial–mesenchymal transition. Furthermore, LHFPL6 expression showed a positive correlation with the abundance of M2 macrophages, which are potent immunosuppressors.Conclusion: LHFPL6 could be a prognostic biomarker and therapeutic target for GC.Keywords: gastric cancer, LHFPL6, biomarker, EMT, M2 macrophagesLiu YJYin SYZeng SHHu YDWang MQHuang PLi JPDove Medical Pressarticlegastric cancerlhfpl6biomarkeremtm2 macrophagesTherapeutics. PharmacologyRM1-950ENPharmacogenomics and Personalized Medicine, Vol Volume 14, Pp 1483-1504 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gastric cancer lhfpl6 biomarker emt m2 macrophages Therapeutics. Pharmacology RM1-950
spellingShingle	gastric cancer lhfpl6 biomarker emt m2 macrophages Therapeutics. Pharmacology RM1-950 Liu YJ Yin SY Zeng SH Hu YD Wang MQ Huang P Li JP Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation
description	Yuan-Jie Liu,1– 3,&ast; Sheng-Yan Yin,2,3,&ast; Shu-Hong Zeng,2,3 Yi-Dou Hu,1 Meng-Qi Wang,2,3 Pan Huang,1 Jie-Pin Li1– 3 1Department of Oncology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, 215600, People’s Republic of China; 2Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, 210029, People’s Republic of China; 3No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jie-Pin Li; Pan HuangDepartment of Oncology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Chang ‘an South Road No. 77, Zhangjiagang, Jiangsu, 215600, People’s Republic of ChinaTel +8615150224526; +8613921976647Email zjgzy027@njucm.edu.cn; yezipan2020@126.comPurpose: The identification of biomarkers and effective therapeutic targets for gastric cancer (GC), the most common cause of cancer-related deaths around the world, is currently a major focus in research. Here, we examined the utility of LHFPL6 as a prognostic biomarker and therapeutic target for GC.Methods: We explored the clinical relevance, function, and molecular role of LHFPL6 in GC using the MethSurv, cBioPortal, TIMER, Gene Expression Profiling Interactive Analysis, ONCOMINE, MEXPRESS, and EWAS Atlas databases. The GSE118919, GSE29272, and GSE13861 datasets were used for differential expression analysis. Using The Cancer Genome Atlas, we developed a Cox regression model and assessed the clinical significance of LHFPLs. In addition, we used the “CIBERSORT” algorithm to make reliable immune infiltration estimations. Western blot and immunohistochemistry were used to examine protein expression. Cell migration and invasion were assessed using transwell experiments. THP-1-derived macrophages and GC cells were co-cultured in order to model tumor–macrophage interactions in vitro. The levels of CD206 and CD163 were measured using immunofluorescence assays. The results were visualized with the “ggplot2” and “circlize” packages.Results: Our results showed that in GC, LHFPL6 overexpression was significantly associated with a poor prognosis. Our findings also suggested that LHFPL6 may be involved in the activation of the epithelial–mesenchymal transition. Furthermore, LHFPL6 expression showed a positive correlation with the abundance of M2 macrophages, which are potent immunosuppressors.Conclusion: LHFPL6 could be a prognostic biomarker and therapeutic target for GC.Keywords: gastric cancer, LHFPL6, biomarker, EMT, M2 macrophages
format	article
author	Liu YJ Yin SY Zeng SH Hu YD Wang MQ Huang P Li JP
author_facet	Liu YJ Yin SY Zeng SH Hu YD Wang MQ Huang P Li JP
author_sort	Liu YJ
title	Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation
title_short	Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation
title_full	Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation
title_fullStr	Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation
title_full_unstemmed	Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation
title_sort	prognostic value of lhfpl tetraspan subfamily member 6 (lhfpl6) in gastric cancer: a study based on bioinformatics analysis and experimental validation
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/1ee5f4adf0d14b43b2df0bf2afc698ed
work_keys_str_mv	AT liuyj prognosticvalueoflhfpltetraspansubfamilymember6lhfpl6ingastriccancerastudybasedonbioinformaticsanalysisandexperimentalvalidation AT yinsy prognosticvalueoflhfpltetraspansubfamilymember6lhfpl6ingastriccancerastudybasedonbioinformaticsanalysisandexperimentalvalidation AT zengsh prognosticvalueoflhfpltetraspansubfamilymember6lhfpl6ingastriccancerastudybasedonbioinformaticsanalysisandexperimentalvalidation AT huyd prognosticvalueoflhfpltetraspansubfamilymember6lhfpl6ingastriccancerastudybasedonbioinformaticsanalysisandexperimentalvalidation AT wangmq prognosticvalueoflhfpltetraspansubfamilymember6lhfpl6ingastriccancerastudybasedonbioinformaticsanalysisandexperimentalvalidation AT huangp prognosticvalueoflhfpltetraspansubfamilymember6lhfpl6ingastriccancerastudybasedonbioinformaticsanalysisandexperimentalvalidation AT lijp prognosticvalueoflhfpltetraspansubfamilymember6lhfpl6ingastriccancerastudybasedonbioinformaticsanalysisandexperimentalvalidation
_version_	1718418689466826752

Prognostic Value of LHFPL Tetraspan Subfamily Member 6 (LHFPL6) in Gastric Cancer: A Study Based on Bioinformatics Analysis and Experimental Validation

Ejemplares similares